Pfizer Breaks Ground for New Biologics Facility

Pfizer broke ground for its new biologics clinical manufacturing facility in Andover, MA, and will invest more than $200 million to enable the production of complex biologics and vaccines. The new five-story building is expected to be operational by January 2019, and will add approximately 75 new jobs.  

The Andover campus currently includes seven buildings, which house laboratories, clinical and commercial manufacturing suites, and support areas. It also includes a multiproduct manufacturing facility, which allows clinical and commercial products to be manufactured simultaneously.

The new clinical manufacturing facility is designed with five independent manufacturing suites to support Pfizer’s complex and diverse biologics research efforts. The facility will employ flexible design to enable next generation manufacturing strategies and will leverage single-use bioreactors and disposable process technologies.

“The expansion of Pfizer’s presence in Andover will provide state-of-the-art manufacturing to help bring new medicines and vaccines to the patients we serve,” said John Ludwig, senior vice president, BioTherapeutics Pharmaceutical Sciences in Pfizer R&D. “Andover is a crucial part of our global footprint for both clinical and commercial manufacturing, and we believe it provides an attractive location for growth in the coming years.”